Spine Art POLITICAL

Target: Spineart SA, Switzerland Domain: Political Research date: 28 October 2026 Coverage: Corporate political communications, territorial operations, governance, advocacy, institutional relationships, ownership, and leadership conduct.

Corporate Communications & Public Stance

Official communications

Spineart SA describes itself as a Swiss medical-technology company founded in Geneva in 2005, operating internationally in spinal implants, minimally invasive surgery, motion-preservation technologies, and robotic surgical guidance. Its corporate profile reports operations serving more than 60 countries. The company maintains a public corporate communications channel through its website. Its commercial mission, as presented on the website in October 2026, concerns surgical innovation and patient outcomes. ¹

The corporate history page identifies the company’s original objectives as simplifying surgical procedures, developing an artificial cervical disc, and improving spinal-fusion technologies. Its marketing emphasizes Swiss manufacturing expertise and surgical innovation. The page was accessible on 28 October 2026; the foundational activities date to 2005 and the product history includes a 2008 introduction. ²

On 26 September 2025, Spineart SA announced a CHF 25 million capital increase involving Gimv and EGS Beteiligungen. The company publicly presented the transaction as supporting technology development and international expansion, particularly in Europe and the United States. The announcement remained publicly accessible on 28 October 2026; the persistence of the communication therefore extended approximately thirteen months. Its precise readership is not disclosed. ³

On 26 August 2026, Spineart SA and eCential Robotics announced FDA clearance for the PERLA TL application on the Op.n robotic navigation platform. The communication concerned medical-device compatibility and surgical workflows. It was publicly accessible approximately two months after publication, with an unrestricted corporate-website audience and no disclosed readership figures. ⁴

Israel-Palestine statements

No public evidence identified of an official Spineart SA statement specifically addressing the Israel-Palestine conflict.

No public evidence identified of an official company declaration supporting Israeli military operations, settlement expansion, Palestinian political organizations, or a specific position on the conflict.

Comparative public posture

Spineart’s accessible corporate news archive contains dated announcements concerning product development, clinical studies, regulatory clearances, manufacturing, investment, and commercial partnerships through August 2026. The archive does not establish a comparative pattern of public political commentary on Ukraine, Black Lives Matter, or the Israel-Palestine conflict. ⁵

No public evidence identified establishing a company-level double standard between communications about different geopolitical conflicts.

Market framing

Gimv’s public investment description characterizes Spineart as a medical-device company pursuing surgical innovation, physician training, and expansion in Europe and the United States. Gimv identifies its initial investment year as 2016. This corporate investment relationship was still presented on Gimv’s portfolio website on 28 October 2026. ⁶

No public evidence identified of Spineart SA explicitly describing its activities as advancing Israeli geopolitical objectives.

28 October 2026 - Spineart SA’s original announcement dated 26 September 2025, entitled “Gimv and EGS Beteiligungen reinforce strategic support for SPINEART with CHF 25 million capital increase to accelerate global growth,” remained publicly accessible at its original corporate URL without login or access restrictions. The opened page displayed the original publication date, identified Gimv and EGS Beteiligungen as investors, and reproduced the CHF 25 million financing announcement, including statements from Spineart executives and investor representatives. Spineart’s official news archive independently retained a dated entry linking to the announcement. These primary corporate records confirm the existing statement under “Official communications” that the announcement remained publicly accessible on 28 October 2026, approximately thirteen months after publication. No correction is required to that statement. The records establish public availability but provide no readership statistics or evidence of uninterrupted availability throughout the intervening period. ^{3, 5}

28 October 2026 - Spineart SA’s original announcement dated 26 August 2026, entitled “Spineart and eCential Robotics receive FDA 510(k) clearance for the PERLA TL application for use with eCential Op.n navigation system for robotic procedures,” remained publicly accessible at its original corporate URL without login or access restrictions. The opened page displayed its publication date and the announcement concerning FDA 510(k) clearance for use of the PERLA TL application with eCential Robotics’ Op.n navigation and robotic-assisted platform. Spineart’s official news archive also retained the announcement as a dated Innovation entry linking to the original article. These primary corporate records confirm the existing statement under “Official communications” that the announcement remained publicly accessible in October 2026, approximately two months after publication. No correction is required to that statement. The accessible records do not disclose readership figures or establish uninterrupted availability between publication and verification. ^{4, 5}

Operations in Occupied or Contested Territories

Documented international corporate footprint

Spineart SA’s official contact directory, accessed on 28 October 2026, identifies its Swiss headquarters and a French manufacturing operation, together with offices or operating entities in the United States, Germany, Spain, Italy, and the United Kingdom. The company identifies its UK entity as Spineart UK LTD. The webpage does not provide historical opening dates for each office; the current listing confirms that the company continued publicly representing these locations in October 2026. ⁷

SPINEART (UK) LTD, company number 08328402, was incorporated on 12 December 2012 and is recorded as active by UK Companies House. The registered address is in Portsmouth, England. This statutory registration remained active in the records accessed during October 2026. ⁸

Israeli commercial presence

No currently accessible corporate disclosure reviewed for this audit established the name, contractual status, or operating dates of a specific Israeli Spineart distributor, subsidiary, or hospital customer.

No public evidence identified establishing a verified Spineart SA contract with the Israeli Ministry of Defense or Israel Defense Forces.

No public evidence identified establishing deliveries by Spineart SA to hospitals or medical facilities located in Israeli settlements.

No public evidence identified establishing a Spineart SA branch, facility, subsidiary, or production operation in an Israeli settlement, occupied East Jerusalem, or the occupied Golan Heights.

Potential intermediaries

Spineart SA publicly identifies eCential Robotics and SpinEM Robotics as medical-technology partners. The identified collaborations concern spinal navigation, surgical robotics, and related medical devices; the source does not establish a military customer, settlement intermediary, or Israeli defense procurement relationship. The public company profile continued displaying these partnerships on 28 October 2026. ¹

On 30 April 2024, Spineart announced a €10 million strategic investment in SpinEM Robotics. The identified recipient was SpinEM Robotics, and the announced purpose was development of navigation and robotic-assistance technologies for spinal surgery. The announcement was made on spineart.com and remained publicly accessible in October 2026; the precise closing conditions, current equity percentage, and termination provisions were not disclosed on the opened page. ⁹

Legal and regulatory scrutiny

No public evidence identified of Spineart SA being named in an Israel-Palestine-related enforcement action, settlement-related legal proceeding, or government procurement exclusion.

No verified Spineart SA entry was identified in the authoritative settlement-related business sources examined during this research.

Civil society campaigns

No public evidence identified of a specifically documented BDS campaign targeting Spineart SA.

No public evidence identified of an organized divestment campaign concerning Spineart’s alleged involvement in Israeli settlement operations.

No public evidence identified of a company response to such a campaign.

Internal Governance, Content & Retail Policies

Employee relations

Spineart SA’s corporate profile identifies executive responsibilities across commercial operations, administration, technology, product development, finance, regulatory affairs, and operations. The public organizational presentation accessed in October 2026 does not establish an Israel-Palestine-specific employee-speech policy. ¹⁰

No public evidence identified of disciplinary action against Spineart employees for Palestinian solidarity activities.

No public evidence identified of employment litigation involving political symbols, Gaza-related communications, or anti-BDS employee activity.

No public evidence identified of company action against unions because of Israel-Palestine advocacy.

Platform and editorial governance

Spineart’s publicly described PERLA TL application is intended for medical surgical navigation and robotic workflows. Its announced FDA clearance on 26 August 2026 relates to the eCential Op.n platform. The announcement does not establish a consumer social-media service, political-content platform, or content-moderation function. ⁴

No public evidence identified of Israel-Palestine-related platform censorship, political content removal, or algorithmic discrimination attributable to Spineart SA.

No public evidence identified of a regulator investigating Spineart for suppression of Palestinian political expression.

Retail and supply-chain practices

The company’s public portfolio describes sterile spinal implants, navigation-related technologies, and surgical products. Its disclosed commercial purpose is medical-device supply to surgeons and hospitals. The official company profile was accessible in October 2026. ¹

No public evidence identified of settlement-origin goods being marketed by Spineart SA.

No public evidence identified of disputed-origin labelling, settlement-product sourcing, or regulatory action concerning such goods.

Internal governance disclosures

Companies House identifies Gino Jacques François Poggiali as an active person with significant control over SPINEART (UK) LTD, notified on 1 August 2022. The registered nature of control is significant influence or control; the record does not establish that he personally owns a specified percentage of Spineart SA. ¹¹

No public evidence identified of a shareholder resolution concerning Israel-Palestine due diligence being suppressed by Spineart SA.

Brand Heritage & State Partnerships

Brand heritage

Spineart states that its company was founded in Geneva in 2005 to improve spinal surgery. Its public corporate history describes clinical and engineering motivations, including development of the BAGUERA cervical disc. No military or national-security founding mandate is described on the company history page accessed in October 2026. ²

Spineart’s homepage, accessed on 28 October 2026, markets products through medical categories including motion preservation, posterior fixation, and related surgical technologies. ¹²

State honors

Spineart’s announcement of FDA approval for the BAGUERA C cervical disc, dated 11 August 2026, states that the company received the Prix de l’Economie Genevoise 2022 for its contribution to technological innovation, commercial activity, employment, and ESG principles. The award reference concerns Geneva’s regional economy. The announcement was publicly accessible in October 2026. ¹³

No public evidence identified of Spineart receiving an Israeli government award connected with geopolitical advocacy or military activity.

Institutional and state partnerships

Spineart and eCential Robotics announced FDA clearance of their surgical-technology integration in August 2026. The FDA action concerned medical-device regulation in the United States; the named commercial parties were Spineart and eCential Robotics. The corporate announcement was published on spineart.com and remained accessible in October 2026. ⁴

No public evidence identified of Spineart SA sponsoring an Israeli government public-diplomacy campaign.

No public evidence identified of Spineart SA hosting Israeli government officials in connection with a political advocacy programme.

No public evidence identified of formal non-commercial institutional partnerships designed to promote Israeli state political objectives.

Lobbying, Advocacy, Financing & Logistics

Political lobbying

No public evidence identified establishing lobbying by Spineart SA concerning Israeli policy, anti-BDS legislation, recognition of Palestinian statehood, settlement policy, or arms transfers.

No public evidence identified of a Spineart political action committee making contributions connected with Israel-Palestine advocacy.

No public evidence identified of corporate membership in AIPAC, CFI, or a comparable regional political lobbying organization.

Corporate financing

On 26 September 2025, Spineart SA announced a CHF 25 million capital increase supported by Gimv and EGS Beteiligungen. The identified recipient of this investment was Spineart SA, and the published purpose was commercial expansion and development of surgical technology. The announcement does not describe financing for political advocacy or military organizations. ³

Gimv separately identifies Spineart as a healthcare portfolio company and reports an investment relationship dating from 2016. Its portfolio directory continued to include Spineart in October 2026. ¹⁴

EGS Beteiligungen’s portfolio page identifies Spineart as a Swiss medical-technology investment and reports that it acquired a minority shareholding in 2020. The portfolio relationship was still publicly presented when accessed in October 2026. ¹⁵

An independent Greater Geneva Bern Area announcement dated 6 October 2025 also reported the CHF 25 million investment supported by Gimv and EGS Beteiligungen. The reported purpose was global expansion and innovation in spinal implants. ¹⁶

No public evidence identified of a corporate donation by Spineart SA to the IDF, Friends of the IDF, JNF/KKL, Israeli reservist support organizations, settlement advocacy groups, or military-welfare funds.

No public evidence identified of Spineart charitable matching payments to such organizations.

Corporate asset mobilization

Spineart SA’s 30 April 2024 announcement identified SpinEM Robotics as the beneficiary of its €10 million strategic investment. The announced channel was a medical-technology investment and development partnership publicized on spineart.com; the earliest documented date is 30 April 2024, and the website continued describing the partnership in October 2026. The investment’s current contractual status was not independently verified. ⁹

Spineart’s 26 August 2026 medical-device announcement records integration of PERLA TL with eCential Robotics’ Op.n surgical platform. The named organizations are Spineart and eCential Robotics, the commercial channel is the partners’ medical-technology collaboration, and the stated beneficiaries are surgeons and hospitals. The announcement remained publicly available in October 2026, but no independent information established the number of active installations. ⁴

No public evidence identified of Spineart providing free logistics, equipment, transportation, infrastructure, or medical technology specifically to Israeli armed forces during the Gaza conflict.

No public evidence identified of corporate support for settlement organizations after 19 July 2024.

No public evidence identified of politically directed financing or resource mobilization continuing after the November 2024 ICC arrest warrants.

Corporate Structure & Primary Mission

Corporate identity

Spineart SA presents itself as a Swiss medical-device company established in Geneva in 2005. Its publicly stated commercial activities include spinal implants, clinical technologies, and surgical workflow improvement. The corporate website continued identifying these activities in October 2026. ¹

The company’s official contact directory names Spineart SA, Spineart USA Inc., Spineart Deutschland GmbH, Spineart España SLU, Spineart Italia S.R.L., and Spineart UK LTD. The directory was accessed in October 2026 and does not establish the exact equity ownership of each named entity. ⁷

Investors and beneficial ownership

Gimv identifies Spineart as an investment entered into in 2016. Gimv’s corporate website describes Gimv itself as a European investment company listed on Euronext Brussels. Spineart remained in its publicly presented investment portfolio in October 2026. ^{6, 17}

EGS Beteiligungen reports acquiring a minority investment in Spineart in 2020. Its public portfolio listing does not specify the exact percentage held in October 2026. ¹⁵

The 26 September 2025 announcement confirms both institutional investors participated in additional financing, but does not establish their post-investment ownership percentages or identify every shareholder with at least 10% equity. ³

Historical acquisition

In July 2020, Spineart USA Inc. announced an agreement for Spineart to acquire 100% of Meditech Spine LLC, based in Atlanta. The document identifies Meditech Spine as the acquisition target and reports that Spineart had distributed Meditech products in the United States since 2019. It anticipated completion during July 2020; the agreement document alone does not establish completed acquisition or continuing ownership in October 2026. ¹⁸

Similarly named companies

SPINE ART LIMITED, company number 07556916, was incorporated in England on 9 March 2011. Its separate Companies House record names Daniel John Fagan as an active director. The registration does not establish ownership by Swiss Spineart SA. ¹⁹

Foundational mission

Spineart’s own history describes its objectives as improving the efficiency and quality of spinal surgery and developing medical technologies. No geopolitical founding purpose, state-held golden share, or explicit state-security mandate is identified in the reviewed corporate description. ²

No public evidence identified of an Israeli government controlling stake in Spineart SA.

No public evidence identified of a constitutional provision obliging Spineart SA to advance Israeli geopolitical objectives.

Executive & Leadership Footprint

Current named leadership and board

Spineart’s October 2026 corporate leadership page names Jérôme Trividic as CEO; Gino Poggiali as chief administrative officer; Alessia Erlingher as chief commercial officer; Guillaume Amblard as chief product officer; Max Lok as a regulatory and quality executive; Yohan Stalder as an operations executive; Stephan Cori as a finance executive; and Laurent Nodé-Langlois as CTO. ¹⁰

The same corporate page names Kevin Klein, Bart Diels, and Gautier Lefebvre as Gimv representatives; Christian Pfab and Dominik Sauter as EGS Beteiligungen representatives; Jean-Philippe Favre as a minority-shareholder representative; and Stéphane Mugnier-Jacob and Jérôme Levieux as founders and board directors. Their current public corporate affiliations were displayed in October 2026. ¹⁰

Named-entity political search record

• Spineart SA - target company; searched for Israel-Palestine statements, military contributions, settlement activity, and geopolitical lobbying; no public evidence identified of the specified political acts. Its documented commercial business is medical technology. ¹
• Gimv - investor since 2016; searched for Spineart-related political financing, Israel-Palestine advocacy, and settlement sponsorship; searched, none found in the reviewed material. ⁶
• EGS Beteiligungen AG - minority investor since 2020; searched for Israel-Palestine-related activity attributable to its Spineart holding; searched, none found in the reviewed material. ¹⁵
• Spineart USA Inc. - US group entity; searched for relevant advocacy, political donations, and military contracts; searched, none found in the reviewed material. ⁷
• SPINEART (UK) LTD - UK group entity; searched for political donations, lobbying, and Israel-Palestine activity; searched, none found in the reviewed material. ⁸
• Spineart Deutschland GmbH - German group entity; searched for political sponsorship and relevant institutional ties; searched, none found in the reviewed material. ⁷
• Spineart España SLU - Spanish group entity; searched for political sponsorship and relevant institutional ties; searched, none found in the reviewed material. ⁷
• Spineart Italia S.R.L. - Italian group entity; searched for political sponsorship and relevant institutional ties; searched, none found in the reviewed material. ⁷
• Meditech Spine LLC - announced US acquisition target; searched for Israel-related contracts, military supply, and advocacy; searched, none found in the reviewed material. Current ownership requires verification. ¹⁸
• SpinEM Robotics - surgical-navigation investment recipient; searched for Israeli military customers and settlement relationships; searched, none found in the reviewed material. ⁹
• eCential Robotics - surgical robotics partner; searched for Israeli military and state-security relationships connected to Spineart; searched, none found in the reviewed material. ⁴
• Jérôme Trividic - CEO; searched for IDF/FIDF donations, settlement advocacy, political statements, and defense affiliations; searched, none found in the reviewed material. ¹⁰
• Stéphane Mugnier-Jacob - co-founder and board director; searched for regional political advocacy, military donations, and defense or settlement affiliations; searched, none found in the reviewed material. ¹⁰
• Jérôme Levieux - co-founder and board director; searched for regional political advocacy, military donations, and defense or settlement affiliations; searched, none found in the reviewed material. ¹⁰
• Gino Poggiali - administrative executive and registered significant-control person for the UK company; searched for regional political financing and relevant organizational affiliations; searched, none found in the reviewed material. ¹¹
• Kevin Klein - Gimv representative; searched for Israel-Palestine advocacy, defense directorships, and settlement-NGO affiliations; searched, none found in the reviewed material. ¹⁰
• Bart Diels - Gimv representative; searched for regional political donations, defense directorships, and settlement-NGO affiliations; searched, none found in the reviewed material. ⁶
• Gautier Lefebvre - Gimv representative; searched for regional political donations, defense directorships, and settlement-NGO affiliations; searched, none found in the reviewed material. ⁶
• Christian Pfab - EGS Beteiligungen representative; searched for political financing, military-support organizations, and geopolitical lobbying; searched, none found in the reviewed material. ¹⁰
• Dominik Sauter - EGS Beteiligungen representative; searched for political financing, military-support organizations, and geopolitical lobbying; searched, none found in the reviewed material. ¹⁵
• Jean-Philippe Favre - minority-shareholder representative; searched for political donations, Israeli state advocacy, and settlement affiliations; searched, none found in the reviewed material. ¹⁰
• Alessia Erlingher - commercial executive; searched for political advocacy and military-welfare financing; searched, none found in the reviewed material. ¹⁰
• Guillaume Amblard - product executive; searched for defense-industry and regional political affiliations; searched, none found in the reviewed material. ¹⁰
• Max Lok - regulatory and quality executive; searched for regional political advocacy and defense-industry affiliations; searched, none found in the reviewed material. ¹⁰
• Yohan Stalder - operations executive; searched for political advocacy, military financing, and relevant defense affiliations; searched, none found in the reviewed material. ¹⁰
• Stephan Cori - finance executive; searched for political financing, military donations, and lobbying affiliations; searched, none found in the reviewed material. ¹⁰
• Laurent Nodé-Langlois - CTO; searched for Israeli defense-sector relationships and political advocacy; searched, none found in the reviewed material. ⁴
• Shane Aiken - UK company director; searched for political donations and Israel-Palestine advocacy; searched, none found in the reviewed material. ²⁰

Personal philanthropy

No public evidence identified of donations by the named founders, executives, or identified investor representatives to Friends of the IDF, the Jewish National Fund, Israeli military-welfare organizations, or settlement organizations.

No public evidence identified of an executive-controlled foundation making grants for those purposes.

Executive communications

In the September 2025 financing announcement, CEO Jérôme Trividic discussed commercial growth, surgical innovation, robotics, and expansion in Europe and the United States. Bart Diels, Gautier Lefebvre, Dominik Sauter, and Christian Pfab also made statements concerning the investment and the company’s growth. The statement was published on Spineart’s corporate website on 26 September 2025 and was still accessible approximately thirteen months later. No audience figures are provided. ³

On 11 August 2026, CEO Jérôme Trividic commented publicly on FDA approval of the BAGUERA C cervical disc and its medical applications. This communication was published on spineart.com and remained accessible in October 2026. ¹³

No public evidence identified of statements by these executives advocating Israeli military operations, settlement expansion, restrictions on Palestinian rights, or anti-BDS legislation.

Board memberships and affiliations

The company’s public governance presentation documents board representation associated with Gimv, EGS Beteiligungen, and the founding shareholders. No Israel-Palestine advocacy role is stated in that official presentation. ¹⁰

No public evidence identified of the identified executives or directors holding a leadership position in a specifically Israel-Palestine-focused lobbying organization.

No public evidence identified of a named controlling principal publicly organizing fundraising for Israeli military operations.